Pheochromocytoma (PHEO) and Paraganglioma (PGL)

Pacak, Karel; Taïeb, David

doi:10.3390/books978-3-03921-655-0

dc.contributor.author	Pacak, Karel	*
dc.contributor.author	Taïeb, David	*
dc.date.accessioned	2021-02-11T22:47:21Z
dc.date.available	2021-02-11T22:47:21Z
dc.date.issued	2019	*
dc.date.submitted	2019-12-09 11:49:16	*
dc.identifier	42657	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/56155
dc.description.abstract	This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.	*
dc.language	English	*
dc.subject	R5-920	*
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	polycythemia	*
dc.subject.other	peptide receptor radiotherapy	*
dc.subject.other	n/a	*
dc.subject.other	vasculogenesis	*
dc.subject.other	catecholamines	*
dc.subject.other	neuroendocrine	*
dc.subject.other	GTV	*
dc.subject.other	adaptive immunity	*
dc.subject.other	therapy resistance	*
dc.subject.other	histology	*
dc.subject.other	transgenic mice	*
dc.subject.other	cryoablation	*
dc.subject.other	spheroids	*
dc.subject.other	energy metabolism	*
dc.subject.other	somatostatinoma	*
dc.subject.other	angiogenesis	*
dc.subject.other	pheochromocytoma	*
dc.subject.other	SDHD	*
dc.subject.other	percutaneous ethanol injection	*
dc.subject.other	metanephrines	*
dc.subject.other	SDHB	*
dc.subject.other	global longitudinal strain	*
dc.subject.other	mutation	*
dc.subject.other	normetanephrines	*
dc.subject.other	catecholamine	*
dc.subject.other	PASS	*
dc.subject.other	PGL	*
dc.subject.other	177Lu-DOTATATE	*
dc.subject.other	chromosomal alteration	*
dc.subject.other	speckle-tracking echocardiography	*
dc.subject.other	lL-6	*
dc.subject.other	dog	*
dc.subject.other	percutaneous ablation	*
dc.subject.other	stem-like tumor cells	*
dc.subject.other	EPAS1	*
dc.subject.other	neural crest	*
dc.subject.other	fluorescence imaging	*
dc.subject.other	neutrophil	*
dc.subject.other	xenograft	*
dc.subject.other	inflammation	*
dc.subject.other	head and neck	*
dc.subject.other	weighted standard deviation	*
dc.subject.other	FGF21	*
dc.subject.other	calorimetry	*
dc.subject.other	HIF	*
dc.subject.other	average real variability	*
dc.subject.other	next-generation sequencing	*
dc.subject.other	adrenocortical carcinoma	*
dc.subject.other	carotid body	*
dc.subject.other	hypoxia-inducible factor	*
dc.subject.other	paraganglioma	*
dc.subject.other	succinate dehydrogenase	*
dc.subject.other	blood pressure variability	*
dc.subject.other	arrhythmia	*
dc.subject.other	mortality	*
dc.subject.other	NF1	*
dc.subject.other	toll-like receptor	*
dc.subject.other	GAPP	*
dc.subject.other	NET	*
dc.subject.other	subclinical systolic dysfunction	*
dc.subject.other	pheochromocytoma and paraganglioma	*
dc.subject.other	PET-CT	*
dc.subject.other	pan-cancer analysis	*
dc.subject.other	mouse pheochromocytoma cells	*
dc.subject.other	innate immunity	*
dc.subject.other	neurogenesis	*
dc.subject.other	neuroendocrine tumor	*
dc.subject.other	obesity	*
dc.subject.other	hypotension	*
dc.subject.other	hypoxia	*
dc.subject.other	CNV detection	*
dc.subject.other	18F-FDOPA	*
dc.subject.other	comparative genomics	*
dc.subject.other	adrenomedullary function	*
dc.subject.other	PCC	*
dc.subject.other	pathogen-associated molecular patterns	*
dc.subject.other	adrenal tumor	*
dc.subject.other	radiotherapy	*
dc.subject.other	11C-hydroxy-ephedrine	*
dc.subject.other	radiofrequency ablation	*
dc.subject.other	PPGL	*
dc.subject.other	minimally invasive procedure	*
dc.subject.other	sporadic	*
dc.subject.other	diabetes mellitus	*
dc.subject.other	adrenal incidentaloma	*
dc.subject.other	germline mutation	*
dc.subject.other	immunotherapy	*
dc.subject.other	VHL	*
dc.subject.other	immunohistochemistry	*
dc.subject.other	metastatic OR malignant pheochromocytoma	*
dc.subject.other	erythropoietin	*
dc.subject.other	postoperative	*
dc.subject.other	targeted therapy	*
dc.subject.other	PRRT	*
dc.subject.other	metastatic	*
dc.subject.other	mitochondria	*
dc.subject.other	T cell	*
dc.subject.other	TCA cycle	*
dc.subject.other	meta-analysis	*
dc.subject.other	pseudohypoxia	*
dc.subject.other	ectopic secretion	*
dc.subject.other	radiosensitization	*
dc.subject.other	chromogranin A	*
dc.subject.other	hereditary	*
dc.subject.other	hypertension	*
dc.subject.other	PET	*
dc.subject.other	phosphorylation tyrosine hydroxylase	*
dc.title	Pheochromocytoma (PHEO) and Paraganglioma (PGL)	*
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03921-655-0	*
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783039216550	*
oapen.relation.isbn	9783039216543	*
oapen.pages	380	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/